Perspective Therapeutics (NYSEAMERICAN:CATX) Given New $13.00 Price Target at HC Wainwright

Perspective Therapeutics (NYSEAMERICAN:CATX) had its price objective raised by HC Wainwright from $12.00 to $13.00 in a report issued on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other equities analysts also recently commented on the company. Truist Financial set a $12.00 target price on Perspective Therapeutics in a research note on Tuesday, March 17th. BTIG Research reissued a “buy” rating and issued a $14.00 price target on shares of Perspective Therapeutics in a report on Tuesday, March 17th. Wedbush restated an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research report on Wednesday, March 18th. Piper Sandler assumed coverage on Perspective Therapeutics in a research note on Thursday, February 19th. They set an “overweight” rating and a $16.00 price objective for the company. Finally, UBS Group increased their target price on Perspective Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, March 18th. One investment analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $12.63.

Perspective Therapeutics Stock Performance

CATX stock opened at $4.24 on Monday. Perspective Therapeutics has a 1-year low of $1.60 and a 1-year high of $6.16. The firm has a fifty day moving average price of $4.41 and a two-hundred day moving average price of $3.45. The company has a current ratio of 5.17, a quick ratio of 5.17 and a debt-to-equity ratio of 0.01.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its quarterly earnings results on Monday, March 16th. The company reported ($0.51) earnings per share (EPS) for the quarter. The business had revenue of $0.04 million during the quarter. Perspective Therapeutics had a negative return on equity of 41.79% and a negative net margin of 11,665.27%. As a group, analysts anticipate that Perspective Therapeutics will post -0.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its position in shares of Perspective Therapeutics by 5.0% during the 3rd quarter. Vanguard Group Inc. now owns 3,437,865 shares of the company’s stock worth $11,792,000 after buying an additional 163,532 shares in the last quarter. Avidity Partners Management LP increased its position in shares of Perspective Therapeutics by 7.2% during the 4th quarter. Avidity Partners Management LP now owns 3,210,733 shares of the company’s stock valued at $8,830,000 after purchasing an additional 216,700 shares during the period. Geode Capital Management LLC raised its stake in shares of Perspective Therapeutics by 15.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock worth $4,758,000 after buying an additional 188,887 shares in the last quarter. Opaleye Management Inc. bought a new stake in shares of Perspective Therapeutics in the 4th quarter worth $3,257,000. Finally, State Street Corp raised its stake in shares of Perspective Therapeutics by 3.3% in the 4th quarter. State Street Corp now owns 1,141,247 shares of the company’s stock worth $3,138,000 after buying an additional 36,543 shares in the last quarter. Institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.